Study Summary
This is a phase I clinical study to evaluate the safety and tolerability of FAST targeted chimeric antigen receptor (CAR)-T cells (PTC13) in patients with carcinoembryonic antigen (CEA)-positive advanced malignant solid tumors, and to obtain the maximum tolerated dose of FAST CAR-T (PTC13) and phase II Recommended dose.
Want to learn more about this trial?
Request More InfoInterventions
Intraperitoneal infusion of FAST CEA-targeted CAR-TBIOLOGICAL
Intraperitoneal infusion of FAST CEA-targeted CAR-T (PTC13); Subjects will be treated with Fludarabine and Cyclophosphamide based lymphodepleting chemotherapy before CAR-T cell infusion.
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| the First Affiliated Hospital, Zhejiang University School of Medicine (FAHZU) | Hangzhou | Zhejiang | China |